Delavirdine

• CAT Number: I001420
• CAS Number: 136817-59-9
• Molecular Formula: C22H28N6O3S
• Molecular Weight: 456.56
• Purity: ≥95%
• Synonyms: N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
• Target: HIV
• Solubility: 10mM in DMSO
• Storage: Store at -20C
• IC50: 0.26 uM (Recombinant HIV-1 RT) [1]
• InChI: InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
• InChIKey: WHBIGIKBNXZKFE-UHFFFAOYSA-N
• SMILES: CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C

Delavirdine（Cat No.:I001420）is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It works by binding to the reverse transcriptase enzyme, blocking the conversion of viral RNA into DNA, which is essential for viral replication. Delavirdine is typically used in combination with other antiretroviral drugs to enhance efficacy and reduce the risk of drug resistance. It is metabolized primarily by the liver and may interact with other medications. Clinical use requires careful monitoring of liver function and potential drug interactions.

Reference

1:Effect of six antiretroviral drugs (delavirdine, stavudine, lamivudine, nelfinavir, amprenavir and lopinavir/ritonavir in association) on albino pregnant rats (Rattus norvegicus Albinus, Rodentia, Mammalia): biological assay. Nakamura MU, Araujo Júnior E, Simões JM, Oliveria RM, Kulay LJ.Ceska Gynekol. 2014 Aug;79(4):295-304. PMID: 25398151 2:Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Kuo YC, Chung CY.Colloids Surf B Biointerfaces. 2011 Dec 1;88(2):682-90. doi: 10.1016/j.colsurfb.2011.07.060. Epub 2011 Aug 6. PMID: 21865017 3:Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. Wang Z, Vince R.Bioorg Med Chem. 2008 Apr 1;16(7):3587-95. doi: 10.1016/j.bmc.2008.02.007. Epub 2008 Feb 8. PMID: 18314335 4:Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients. Morse GD, Cohn SE, Shelton MJ, Greisberger C, Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC.Clin Drug Investig. 2003;23(5):323-8. PMID: 17535044 5:Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection. Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW.Clin Drug Investig. 2003;23(4):255-61. PMID: 17535038 6:Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Kuo YC, Su FL.Int J Pharm. 2007 Aug 1;340(1-2):143-52. Epub 2007 Mar 12. PMID: 17418986 7:Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM.Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S224-34. PMID: 17109309 8:Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. McCance-Katz EF, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P.Am J Addict. 2006 Jan-Feb;15(1):23-34. PMID: 16449090 9:Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD.Clin Pharmacokinet. 2005;44(1):99-109. PMID: 15634033 10:Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, Hellmann NS, Arens MQ.J Clin Virol. 2004 Nov;31(3):198-203. PMID: 15465412